PMID- 37247903
OWN - NLM
STAT- MEDLINE
DCOM- 20230602
LR  - 20230602
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 6
DP  - 2023 Jun
TI  - Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients 
      With Palbociclib.
PG  - 2783-2789
LID - 10.21873/anticanres.16447 [doi]
AB  - BACKGROUND/AIM: Palbociclib was the first cyclin-dependent kinase 4 and 6 
      (CDK4/6) inhibitor approved worldwide. Currently, CDK4/6 inhibitors are strongly 
      recommended for endocrine therapy in the first or second line with hormone 
      receptor-positive advanced breast cancer. It is expected the use of CDK4/6 
      inhibitor will further increase. Therefore, the aim was to investigate and better 
      understand the use of palbociclib. PATIENTS AND METHODS: We retrospectively 
      analyzed the data of patients with advanced breast cancer who were treated with 
      palbociclib in three hospitals between 2018 and 2022. Clinical data were obtained 
      from the patients' medical electronic records. RESULTS: A total of 143 patients 
      were enrolled. The median age was 66 years (range=33-89), and the majority 
      (90.9%) were postmenopausal patients. In total, median time-to-treatment 
      discontinuation (TTD) (95% confidence interval, CI) was 7 (6-10) months. Median 
      TTD (95% CI) was 13 (7-20) months for the first or second line, and significantly 
      prolonged compared to TTD for the third or later lines with palbociclib 
      (p<0.0001). The importance of front-line use was indicated. Multivariate analyses 
      showed that no visceral metastasis or first or second line therapy influenced the 
      longer TTD. Between patients above or below 70 years of age, older age did not 
      negatively affect TTD, though there were significantly more cases of dose 
      reduction or withdrawal in patients over 70 years old. The variation of adverse 
      events (AEs) among hospitals was very large (9.0%, 31.3%, 4.5%). We found that 
      understanding of AE management was important. CONCLUSION: This study showed that 
      dose reduction or withdrawal of palbociclib had no harmful effects in Japanese 
      patients. Efficacy was also high in older patients. It is important to manage 
      palbociclib administration more safely and appropriately. A combination of dose 
      reduction and withdrawal is key to this therapeutic strategy.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Morita, Midori
AU  - Morita M
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan; midori@koto.kpu-m.ac.jp.
FAU - Ooe, Asako
AU  - Ooe A
AD  - Breast Surgery Unit, Kyoto Okamoto Memorial Hospital, Kyoto, Japan.
FAU - Ishii, Wataru
AU  - Ishii W
AD  - Breast Surgery Unit, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
FAU - Watanabe, Akira
AU  - Watanabe A
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Matsui, Chise
AU  - Matsui C
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Okuyama, Yuka
AU  - Okuyama Y
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Kitano, Sae
AU  - Kitano S
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Kato, Chikage
AU  - Kato C
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Onishi, Mie
AU  - Onishi M
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Sakaguchi, Koichi
AU  - Sakaguchi K
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Naoi, Yasuto
AU  - Naoi Y
AD  - Division of Endocrine and Breast Surgery, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - G9ZF61LE7G (palbociclib)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Breast Neoplasms/pathology
MH  - Receptor, ErbB-2
MH  - Retrospective Studies
MH  - Adult
MH  - Middle Aged
MH  - Aged, 80 and over
OTO - NOTNLM
OT  - Japanese
OT  - Palbociclib
OT  - breast cancer
OT  - dose reduction
OT  - drug holiday
OT  - older patients
EDAT- 2023/05/30 01:06
MHDA- 2023/05/31 06:42
CRDT- 2023/05/29 20:43
PHST- 2023/03/03 00:00 [received]
PHST- 2023/03/23 00:00 [revised]
PHST- 2023/03/30 00:00 [accepted]
PHST- 2023/05/31 06:42 [medline]
PHST- 2023/05/30 01:06 [pubmed]
PHST- 2023/05/29 20:43 [entrez]
AID - 43/6/2783 [pii]
AID - 10.21873/anticanres.16447 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Jun;43(6):2783-2789. doi: 10.21873/anticanres.16447.